HopeStage
Back to all studies
CompletedNCT01870999

Long-Acting Aripiprazole Injection: Safety and Drug Levels in Schizophrenia

About this titleRead the official source — NCT01870999

This study evaluated the safety of aripiprazole IM depot for people with schizophrenia.

Medication studyAges 18–64United States
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety of aripiprazole IM depot for people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.

Listed locations
Cerritos and 6 more locationsSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNovember 2007
Recruitment status
Completed
Enrollment listed in the registry
41
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 64 Years
Official registry ID
NCT01870999
Official title
Show the full official title

An Open-label Parallel Arm Multiple Dose Tolerability, Pharmacokinetics and Safety Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot Formulation Once Every Four Weeks

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Cerritos · Garden Grove · Glendale

4 more locations
  • Paramount
  • St Louis
  • Willingboro
  • Austin

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety of aripiprazole IM depot for people with schizophrenia.

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including aripiprazole IM depot and aripiprazole tablets.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies